NCT00161668CompletedNot Applicable
Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Wyeth is now a wholly owned subsidiary of Pfizer0 sites500 target enrollmentStarted: October 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 500
Study Overview
Brief Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Study Design
- Study Type
- Observational
- Observational Model
- Defined Population
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Treated by Mylotarg
- •Provide ICF
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Completed
Not Applicable
Observational Study of LamotrigineEpilepsyNCT00299793Northwell Health60
Completed
Phase 4
Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of MagaldrateHealthyNCT06367452Tecnoquimicas10
Completed
Phase 4
Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)Non Alcoholic SteatohepatitisNCT04537780Tanta University44
Completed
Phase 2
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial LipodystrophyFamilial Partial LipodystrophyNonalcoholic SteatohepatitisNAFLDNCT02654977University of Michigan11
Completed
Not Applicable
German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.Fabry DiseaseNCT03135197University Hospital Muenster75